China Medical University

University of North Carolina at Chapel Hill

Yung Shin Pharmaceutical Ind. Co., Ltd.

National Science Council

Yung Shin Pharm. Ind. Co., Ltd.

Industrial Technology Research Institute

Carlsbad Technology, Inc.

Other

China Medical University Hospital

Medical and Pharmaceutical Industry Technology and Development Center

Tairx, Inc.

Yung Shin Pharmaceuticals Industrial Co., Ltd

Sheng-Chu Kuo

Che-Ming Teng

Kuo-Hsiung Lee

Li-Jiau Huang

Jai-Sing Yang

Shiow-Lin Pan

Tian-Shung Wu

Li-Chen Chou

Fang-Yu Lee

Tzong-Der Way

Jih-Hwa Guh

Chih-Shiang Chang

Jing-Gung Chung

Yang-Chang Wu

Chung-Ming Sun

Fang Yu Lee

Mann-Jen Hour

Jang-Chang Lee

Chien-Ting Chen

Ching-Che Huang

Shih-Ming Huang

Ke Chen

Tai-Lin Chen

Min-Tsang Hsieh

Ling-Chu Chang

Hsin-Yi Hung

Hui-Yi Lin

Po-Wu Gean

Hong-Zin Lee

Woei-Cherng Shyu

Feng-Nien Ko

Chang-Hai Tsai

Chen-Huan Lin

Jin-Bin Wu

Wen-Mei Fu

Toshiro Ibuka

Sheng-Chih Chen

Jih-Pyang Wang

Mei-Hua Hsu

Zheng-Yu Yang

Yi Xia

Kenneth F Bastow

On Lee

Wei Lee

Chun-Jen Chen

Chrong-Shiong Hwang

Chung-Y Hsu

Tsang-Miao Huang

Chi-Hung Huang

Kai-Wei Chang

Pi-Tsan Huang

Chih-Hsin Tang

Yen-Fang Wen

Chi-Ying Hung

Wei-Ling Chang

Rong-Sen Yang

Xiaoming Yang

Masuo Goto

Shi-Hong Zhuang

Mei-Chi Fang

Ying-Qian Liu

Mei-Ling Shih

Liu Yang

Hua-Sin Chen

Yong-Long Zhao

Mei-Juan Wang

Wuu-Chian Shin

Mei-Hwai Chen

Zhi-Jun Zhang

Chin-Yi Wu

Keng-Chen Liang

Wei-Lin Chien

Fang-Yuan Lee

Chih-Ya Wang

Ya-Yun Lai

Chung Y Hsu

Ya-Ling Fang

Huei-Wen Chen

Hui K Wang

Leping Li

Jau-Hong Lee

Yung-Yi Cheng

Che-Hing Teng

Chin-Yu Liu

Yu Zhao

Yu-Chian Chen

Chun-Wei Chiang

Meng-Tung Tsai

Keduo Qian

Ju-Fang Liu

Min-tsang Hsieh

Hui-yi Lin

Huei-Wan Chen

Houng-Chin Liou

Dah-Yuu Lu

A series of novel bis(hydroxymethyl) alkanoate derivatives of curcuminoids were designed, and synthesized, which show anticancer activity, and in particular to breast cancer, colon cancer, and prostate cancer.

Derivatives of curcuminoids and use thereof as an anticancer agent

The present disclosure relates to a bicyclic compound, a pharmaceutical composition thereof, and its novel use. More particularly, the present disclosure relates to the bicyclic compound according to Formula I or Formula II, the pharmaceutical composition for treating a stroke, and the use of the bicyclic compound treating the stroke.

Bicyclic compound and pharmaceutical composition thereof for treating stroke and use thereof

The present invention is related to novel 20-sulfonylamidine derivatives of camptothecin (1), method of synthesizing the same, and use thereof as an antitumor agent, for examples an antitumor agent for treating nasopharyngeal, lung, breast or prostate cancer.

[object Object]

The present invention provides a series of derivatives of stilbenoid which are useful as new inhibitory agents against head and neck squamous cell carcinoma (HNSCC) and hepatoma.

Stilbenoid compound as inhibitor for squamous carcinoma and hepatoma and uses thereof

Provided is a compound of the formula I or a pharmaceutically acceptable salt, solvate or stereoisomer thereof:  

2-aryl-4-quinazolinones and their pharmaceutical compositions

2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120(Naform) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A novel intermediate, 2-selenophene 4-quinolone and N,N-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones are also synthesized. These novel intermediates exhibited significant anticancer activities.

2-phenyl-4-quinolones as anticancer agents

2-selenophene-4-quinolones as anticancer agents

2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120 (Naform) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A novel intermediate, 2-selenophene 4-quinolone and N,N-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones are also synthesized. These novel intermediates exhibited significant anticancer activities.

Hydrophilic derivatives of 2-selenophene-4-quinolones as anticancer agents

A compound of Formula I is disclosed as follows: 

Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives

Benzimidazole compounds of formula (I): wherein R, R, R, R, R, X, Y, Z, and Zare defined herein. Also disclosed is a method for treating cancer with benzimidazole compounds.

Benzimidazole compounds and their use as anticancer agents

2-aryl-4-quinolones are converted into phosphates by reacting with tetrabenzyl pyrophosphate to form dibenzyl phosphates thereof, which are then subject to hydrogenation to replace dibenzyl groups with H, followed by reacting with Amberlite IR-120 (Na+ form) to form disodium salts. The results of preliminary screening revealed that these phosphates showed significant anti-cancer activity. A novel intermediate, 2-selenophene 4-quinolone and &#x39b;/, &#x39b;/-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones are also synthesized. These novel intermediates exhibited significant anticancer activities.

Hydrophilic derivatives of 2-aryl-4-quinolones as anticancer agents

The present invention synthesizes a series of selenolo[3,2-c]pyrazole and selenolo[2,3-c]pyrazole derivatives, and discovers their anticancer activity.

Selenolopyrazole derivatives and use thereof as anticancer agents

A fused pyrazolyl compound having an anti-tumor potency of the following formula is synthesized: wherein A is in which n is 0, 1, 2, or 3; Aris benzene, thiophene or furan; Aris furyl; and Aris phenyl; Rand Rindependently are hydrogen, halogen or &#x2014;(CH)OR; Ris hydrogen or alkyl; Ris &#x2014;(CH)-A, wherein r is an integer of 1-5, and Ahas a formula of &#x2014;O&#x2014;C(O)&#x2014;(CRH)&#x2014;NRR; Rand Rindependently are hydrogen, halogen, or alkyl, or Rand Rtogether are &#x2014;O(CH)O&#x2014;; Ris H, halogen, nitro, cyano, alkyl, or aryl; Ris H, alkyl, or aryl; Rand Rindependently are H, alkyl, or aryl; m is 0, 1, 2, 3, 4, 5, or 6; and q is 1, 2, 3, 4, 5, or 6; or a salt thereof.

Fused pyrazolyl compounds having an aminoalkylcarbonyl group

Growing community of inventors

Taichung, Taiwan

Sheng-Chu Kuo